New pill could tame rare blood disorder when other treatments fail
NCT ID NCT07453368
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a daily pill called orelabrutinib for people with autoimmune hemolytic anemia (AIHA) that hasn't responded to standard treatments. AIHA is a condition where the immune system mistakenly attacks red blood cells, causing fatigue and anemia. The trial will enroll 50 adults and try different doses to see if the drug can control the disease and reduce symptoms, while monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Orelabrutinib
- What this could lead to
- If successful, this could offer a new oral treatment option for people with hard-to-treat autoimmune hemolytic anemia, potentially reducing the need for high-dose steroids or transfusions.
- What could go wrong
- This is an early Phase 2 trial with only 50 participants, so results may not apply to everyone. The drug may cause side effects or not work for some patients, and long-term safety is still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tame autoimmune anemia?
- Engineered immune cells take aim at stubborn blood disorder
- Experimental mRNA CAR-T therapy targets autoimmune diseases in first human trial
- New drug combo aims to tame stubborn blood disorders
- New combo aims to tame autoimmune anemia without Long-Term steroids
- Thousands with blood diseases to be tracked in massive chinese registry